ENBUMYST

Launch

bumetanide

NDANASALSPRAY
Approved
Sep 2025
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
3

Mechanism of Action

Henle. The high degree of diuresis is largely due to the unique site of action. The action on the distal tubule is independent of any inhibitory effect on carbonic anhydrase and aldosterone.

Pharmacologic Class:

Loop Diuretic

Indications (5)

edema associated with congestive heart failurehepaticrenal diseaseincluding nephrotic syndrome in adultsheart failure

Clinical Trials (3)

NCT06941415Phase 3Not Yet Recruiting

Bumetanide vs. Furosemide in Cirrhosis

Started Mar 2026
500 enrolled
Cirrhosis
NCT00830531Phase 1Completed

Pilot Study of Bumetanide for Newborn Seizures

Started Jan 2010
43 enrolled
Seizures
NCT00930865Phase 1Completed

Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy Subjects

Started Jul 2009
42 enrolled
Type 2 Diabetes Mellitus

Loss of Exclusivity

LOE Date
Dec 4, 2040
179 months away
Patent Expiry
Dec 4, 2040

Patent Records (3)

Patent #ExpiryTypeUse Code
11123319
Dec 4, 2040
Product
—
11260038
Dec 4, 2040
U-4279
12329731
Dec 4, 2040
Product
U-4279
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers